Skip to main content

Advertisement

SpringerLink
Log in

A 10-year review of survival among patients with metastatic gastrointestinal cancers: a population-based study

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background

This study assesses survival improvement across a decade (2004–2013) among patients with metastatic gastrointestinal cancers in a real-world setting.

Methods

Surveillance, Epidemiology and End Results (SEER) database was accessed and patients with metastatic gastrointestinal carcinomas who have received any form of systemic therapy were included. Patients were grouped into three cohorts based on the year of diagnosis (cohort-1: 2004–2006; cohort-2: 2008–2010; cohort-3: 2012–2013). Overall survival was compared among the three cohorts for each disease site using Kaplan-Meier survival estimates.

Results

A total of 54,992 patients with metastatic gastrointestinal cancers were included in the current analysis. Using Kaplan-Meier survival comparison for the three temporal cohorts, the following survival observations were noted: for patients with metastatic esophageal adenocarcinoma: median survival for cohort-1: 8 months, cohort-2: 9 months, cohort-3: 9 months; P < 0.001; for patients with metastatic esophageal squamous cell carcinoma: median survival cohort-1: 8 months, cohort-2: 8 months, cohort-3: 8 months; P = 0.689; for patients with metastatic gastric adenocarcinoma: median survival for cohort-1: 8 months, for cohort-2: 9 months, for cohort-3: 9 months; P < 0.001; for patients with metastatic colorectal carcinoma: median overall survival for each of the three cohorts: 21 months; P = 0.131; for patients with metastatic pancreatic carcinoma: median survival for cohort-1: 5 months, cohort-2: 5 months, cohort-3: 6 months; P < 0.001; for patients with metastatic hepatocellular carcinoma: median survival of 5 months for each of the three cohorts; P = 0.534); and for patients with metastatic biliary carcinomas: median survival for cohort-1: 7 months, cohort-2: 7 months, cohort-3: 8 months; P = 0.031).

Conclusion

Limited (if any) survival improvement has been observed among patients with metastatic gastrointestinal carcinomas treated with systemic therapy in the decade from 2004 to 2013.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O et al Global, Regional, and National Cancer Incidence, Mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol 2019

  2. Hochster HS, O'Reilly EM, Ajani JA, Venook AP (2007) Section III: Treatment of advanced gastrointestinal cancers. Gastrointest Cancer Res 1(6 Suppl):S8–S12

    PubMed  PubMed Central  Google Scholar 

  3. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J (2015) A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 16:495

    Article  Google Scholar 

  4. He Z, Chen Z, George T, Lipori G, Bian J (2016) Assessing the population representativeness of colorectal cancer treatment clinical trials. 2970–3 p

  5. Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC et al (2008) Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 112(2):228–242

    Article  Google Scholar 

  6. Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S (2018) Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol 9(6):996–1004

    Article  Google Scholar 

  7. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (1975–2016 varying) - linked to county attributes - total U.S., 1969–2017 counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission

  8. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46

    Article  CAS  Google Scholar 

  9. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825

    Article  CAS  Google Scholar 

  10. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703

    Article  Google Scholar 

  11. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281

    Article  CAS  Google Scholar 

  12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

    Article  CAS  Google Scholar 

  13. Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697–4705

    Article  CAS  Google Scholar 

  14. Donia M, Hansen SW, Svane IM (2019) Real-world evidence to guide healthcare policies in oncology. Oncotarget 10(44)

  15. Canoui-Poitrine F, Lievre A, Dayde F, Lopez-Trabada-Ataz D, Baumgaertner I, Dubreuil O et al (2019) Inclusion of older patients with cancer in clinical trials: the SAGE prospective multicenter cohort survey. Oncologist.

  16. Abdel-Rahman O, Karachiwala H (2019) Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials. Int J Color Dis 34(10):1741–1747

    Article  Google Scholar 

  17. Abdel-Rahman O (2019) ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials. Int J Color Dis 34(12):2143–2150

    Article  Google Scholar 

  18. Unger JM, Hershman DL, Fleury ME, Vaidya R (2019) Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol 5(3):326–333

    Article  Google Scholar 

  19. Abdel-Rahman O (2018) Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. J Cancer Res Clin Oncol 144(5):901–908

    Article  CAS  Google Scholar 

  20. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics. Last accessed on 24/11/2019

  21. Kemp R, Prasad V (2017) Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med 15(1):134

    Article  Google Scholar 

  22. Hilal T, Sonbol MB, Prasad V (2019) Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration. JAMA Oncol. 5(6):887–892

    Article  Google Scholar 

  23. Abdel-Rahman O (2019) Outcomes of non-metastatic colon cancer patients in relationship to socioeconomic status: an analysis of SEER census tract-level socioeconomic database. Int J Clin Oncol 24(12):1582–1587

    Article  Google Scholar 

  24. Chandrasoma PT (2018) Chapter 12 - esophageal adenocarcinoma. In: Chandrasoma PT (ed) GERD. Academic Press, pp 341–389

  25. Holowatyj AN, Gigic B, Herpel E, Scalbert A, Schneider M, Ulrich CM (2019) Distinct molecular phenotype of sporadic colorectal cancers among young patients based on multi-omics analysis. Gastroenterology

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, T6G 1Z2, Canada

    Omar Abdel-Rahman

Authors
  1. Omar Abdel-Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Omar Abdel-Rahman.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdel-Rahman, O. A 10-year review of survival among patients with metastatic gastrointestinal cancers: a population-based study. Int J Colorectal Dis 35, 911–920 (2020). https://doi.org/10.1007/s00384-020-03568-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-020-03568-0

Keywords

Search

Navigation